Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

COMPASS Pathways Plc - American Depository Shares (NQ: CMPS )

4.595 +0.035 (+0.77%)
Streaming Delayed Price Updated: 1:00 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about COMPASS Pathways Plc - American Depository Shares

< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
28 29 Next >
Psyched Wellness is The First Public Company To Bring Amanita Muscaria For Human Consumption To The U.S.
Easily identified by its red cap covered with white dots and a white stem, the Amanita muscaria mushroom is probably the most famous and easily recognizable mushroom in the world. Popularized by Lewis... 
Via Benzinga
Compass Pathways: Q3 Earnings Insights
Compass Pathways (NASDAQ:CMPS) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
COMPASS Pathways Announces Third Quarter 2022 Financial Results and Business Highlights
From COMPASS Pathways
Via GlobeNewswire
Compass Pathways, Small Pharma Among Top Psychedelic Movers Of Today
GAINERS: GH Research (NASDAQ:GHRS) shares closed up 3.90% at $10.39 LOSERS: 
Via Benzinga
Compass Pathways's Earnings Outlook
Compass Pathways (NASDAQ:CMPS) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that Compass... 
Via Benzinga
Why Shares of atai Life Sciences Climbed 14.58% on Tuesday
The company specializes in developing psychedelics as therapies. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
Upgrades 
Via Benzinga
EXCLUSIVE: Insider's Peek At Mammoth Of Psychedelics VCs, Palo Santo's Investment Fundamentals & Specificities
(Part one of a four-part series) 
Via Benzinga
15 Global Psychedelics Executives To Keep An Eye On In 2022
As the global psychedelics industry booms, with companies going public, major financings being announced, and celebrities and big investors getting on board, Benzinga has decided to put together a list... 
Via Benzinga
October Recap: Major Psychedelic Drug Stocks Declined 9.9%
In total, thePsychedelic Drug Stock Index went down 9.9% in September and is now down 64.7% YTD. 
Via Talk Markets
Revive Therapeutics, Small Pharma Among Top Psychedelic Movers Of Today
GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 3.00% at $0.87 
Via Benzinga
Psychedelic Stock Gainers And Losers From October 26, 2022
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 5.39% at $0.18 
Via Benzinga
Psychedelic Stock Gainers And Losers From October 25, 2022
GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 6.24% at $10.39 
Via Benzinga
Cannabis Category Performances Ranged From +14.4% To -4.6% This Past Week
The 5 categories in the cannabis sector perform quite differently week to week. Below is a summary of how each category performed last week, in descending order and since the end of September and since... 
Via Talk Markets
Major Psychedelic Stock Downward Trend Continues
The 8 constituents of our Psychedelic Drug Stocks Index continue to collectively show poor performance, down 4.6% more last week and now down 45.5% since the end of August. 
Via Talk Markets
Allied, Small Pharma Among Top Psychedelic Movers Of Today
GAINERS: Allied (OTC:ALID) shares closed up 10.21% at $0.53 
Via Benzinga
Psychedelic Stock Gainers And Losers From October 18, 2022
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 15.76% at $0.14 
Via Benzinga
Psychedelic Stock Gainers And Losers From October 17, 2022
GAINERS: Biomind Labs (OTC:BMNDF) shares closed up 38.18% at $1.52 
Via Benzinga
Psyched: VC Fund Invests $50M In Psychedelics, Musk's 'Exploratory Journeys', Native American Use Of Peyote And More
Palo Santo Closes $50M Investment Fund Palo Santo, a venture capital fund focused on backing and building emerging psychedelic therapeutics companies, recently announced the closing of its $50 million... 
Via Benzinga
Small Pharma, Cybin Among Top Psychedelic Movers Of Today
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 9.12% at $0.12 
Via Benzinga
Psychedelic Stock Gainers And Losers From October 12, 2022
GAINERS: Allied (OTC:ALID) shares closed up 48.05% at $0.48 
Via Benzinga
Compass Pathways Will Lead Two Concurrent Phase 3 Trials On Psilocybin-Assisted Therapy For Depression
Psychedelics biotech company Compass Pathways (NASDAQ: CMPS) announced it will conduct two separate Phase 3 clinical trials to study psilocybin-assisted therapy on Treatment-Resistant Depression... 
Via Benzinga
Numinus Wellness, Small Pharma Among Top Psychedelic Movers Of Today
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 7.61% at $0.12 
Via Benzinga
Psychedelic Drugs Prove Their Worth In Clinical Trials
Novel psychedelic drugs have continuously proven their worth in clinical trials. Just recently, one company revealed that it was in the process of finalizing its Phase 1 first-in-human clinical trial... 
Via PressReach
Psychedelic Stock Gainers And Losers From October 10, 2022
GAINERS: Cybin (AMEX:CYBN) shares closed up 5.51% at $0.63 LOSERS: 
Via Benzinga
Psychedelic Drug Stocks Index Up Slightly This Week
There are 8 stocks in the munKNEE Psychedelic Drug Stocks Index and this article reveals how its constituents performed this week, in descending order, since the end of August and YTD. 
Via Talk Markets
Psychedelic Stock Gainers And Losers From October 6, 2022
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 45.41% at $0.22 
Via Benzinga
Allied, GH Research Among Top Psychedelic Movers Of Today
GAINERS: Allied (OTC:ALID) shares closed up 31.58% at $0.60 
Via Benzinga
Cybin, GH Research Among Top Psychedelic Movers Of Today
GAINERS: Cybin (AMEX:CYBN) shares closed up 20.50% at $0.58 
Via Benzinga
September Cannabis Category Performances Ranged From -6.3% To -39.0%
The performances of the 5 cannabis categories ranged from -6.3% to -39.0% in September, and are now -13.6% to -67.0%, YTD, depending on the category. The S&P 500, in comparison, was -8.6% in September... 
Via Talk Markets
< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
28 29 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.